Cargando…

Neisseria meningitidis Serogroup W, Burkina Faso, 2012

In 2010, Burkina Faso became the first country to introduce meningococcal serogroup A conjugate vaccine (PsA-TT). During 2012, Burkina Faso reported increases in Neisseria meningitidis serogroup W, raising questions about whether these cases were a natural increase in disease or resulted from serogr...

Descripción completa

Detalles Bibliográficos
Autores principales: MacNeil, Jessica R., Medah, Isaïe, Koussoubé, Daouda, Novak, Ryan T., Cohn, Amanda C., Diomandé, Fabien V.K., Yelbeogo, Denis, Kambou, Jean Ludovic, Tarbangdo, Tiga F., Ouédraogo-Traoré, Rasmata, Sangaré, Lassana, Hatcher, Cynthia, Vuong, Jeni, Mayer, Leonard W., Djingarey, Mamoudou H., Clark, Thomas A., Messonnier, Nancy E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3944835/
https://www.ncbi.nlm.nih.gov/pubmed/24571805
http://dx.doi.org/10.3201/eid2003.131407
Descripción
Sumario:In 2010, Burkina Faso became the first country to introduce meningococcal serogroup A conjugate vaccine (PsA-TT). During 2012, Burkina Faso reported increases in Neisseria meningitidis serogroup W, raising questions about whether these cases were a natural increase in disease or resulted from serogroup replacement after PsA-TT introduction. We analyzed national surveillance data to describe the epidemiology of serogroup W and genotyped 61 serogroup W isolates. In 2012, a total of 5,807 meningitis cases were reported through enhanced surveillance, of which 2,353 (41%) were laboratory confirmed. The predominant organism identified was N. meningitidis serogroup W (62%), and all serogroup W isolates characterized belonged to clonal complex 11. Although additional years of data are needed before we can understand the epidemiology of serogroup W after PsA–TT introduction, these data suggest that serogroup W will remain a major cause of sporadic disease and has epidemic potential, underscoring the need to maintain high-quality case-based meningitis surveillance after PsA–TT introduction.